{
"info": {
"nct_id": "NCT03599960",
"official_title": "Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
"inclusion_criteria": "* Newly diagnosed BPDCN established by a blood or bone marrow immunophenotypic diagnosis by flow cytometric and/or by the anatomic pathology study of a skin biopsy using validated diagnostic criteria (Swerdlow SH CE et al., World Health Organisation Classification of Tumors, 2008; Garnache-Ottou et al., 2009; Angelot et al., 2012; Julia et al., 2014) or patients with confirmed isolated skin lesion.\n* 18 years of age or older\n* No prior cytotoxic therapy except <2 week of corticosteroids or hydroxyurea\n* ECOG ≤2\n* Written informed consent\n* Affiliation to the French social security scheme\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Cardiac contra-indication to anthracyclines: cardiac dysfunction events (NYHA grade 3 or 4 and/or LVEF<50%)\n* Hepatocellular abnormalities except if considered related to the BPDCN:\n\n 1. ASAT (SGOT) and/or ALAT (SGPT) > 5 x ULN\n 2. Total bilirubin ≥ 2.5 x ULN\n* Creatinine level >1.5x ULN or creatinine clearance (MDRD)<50 mL/mn\n* Prior thrombotic event\n* Active hepatitis B or C virus infection\n* HIV positive\n* Serious medical or psychiatric illness that could interfere with the completion of treatment\n* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.\n* Pregnant and lactating female patients\n* Patients diagnosed with or treated for another malignancy within 2 years before study enrollment or with residual disease (basal cell carcinoma or cervical carcinoma in situ patients may be enrolled if they have undergone complete resection)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Newly diagnosed BPDCN established by a blood or bone marrow immunophenotypic diagnosis by flow cytometric and/or by the anatomic pathology study of a skin biopsy using validated diagnostic criteria (Swerdlow SH CE et al., World Health Organisation Classification of Tumors, 2008; Garnache-Ottou et al., 2009; Angelot et al., 2012; Julia et al., 2014) or patients with confirmed isolated skin lesion.",
"criterions": [
{
"exact_snippets": "Newly diagnosed BPDCN",
"criterion": "BPDCN diagnosis",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "newly diagnosed"
}
]
},
{
"exact_snippets": "established by a blood or bone marrow immunophenotypic diagnosis by flow cytometric",
"criterion": "blood or bone marrow immunophenotypic diagnosis",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"flow cytometric"
]
}
]
},
{
"exact_snippets": "established by ... anatomic pathology study of a skin biopsy",
"criterion": "anatomic pathology study of a skin biopsy",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"anatomic pathology"
]
}
]
},
{
"exact_snippets": "using validated diagnostic criteria (Swerdlow SH CE et al., World Health Organisation Classification of Tumors, 2008; Garnache-Ottou et al., 2009; Angelot et al., 2012; Julia et al., 2014)",
"criterion": "validated diagnostic criteria",
"requirements": [
{
"requirement_type": "source",
"expected_value": [
"Swerdlow SH CE et al., World Health Organisation Classification of Tumors, 2008",
"Garnache-Ottou et al., 2009",
"Angelot et al., 2012",
"Julia et al., 2014"
]
}
]
},
{
"exact_snippets": "patients with confirmed isolated skin lesion",
"criterion": "isolated skin lesion",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
}
]
},
{
"line": "* 18 years of age or older",
"criterions": [
{
"exact_snippets": "18 years of age or older",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* No prior cytotoxic therapy except <2 week of corticosteroids or hydroxyurea",
"criterions": [
{
"exact_snippets": "No prior cytotoxic therapy",
"criterion": "prior cytotoxic therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "<2 week of corticosteroids",
"criterion": "corticosteroids",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "week"
}
}
]
},
{
"exact_snippets": "<2 week of ... hydroxyurea",
"criterion": "hydroxyurea",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "week"
}
}
]
}
]
},
{
"line": "* ECOG ≤2",
"criterions": [
{
"exact_snippets": "ECOG ≤2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Written informed consent",
"criterions": [
{
"exact_snippets": "Written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "form",
"expected_value": "written"
}
]
}
]
},
{
"line": "* Affiliation to the French social security scheme",
"criterions": [
{
"exact_snippets": "Affiliation to the French social security scheme",
"criterion": "affiliation to the French social security scheme",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Cardiac contra-indication to anthracyclines: cardiac dysfunction events (NYHA grade 3 or 4 and/or LVEF<50%)",
"criterions": [
{
"exact_snippets": "Cardiac contra-indication to anthracyclines",
"criterion": "cardiac contra-indication to anthracyclines",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "cardiac dysfunction events (NYHA grade 3 or 4",
"criterion": "NYHA grade",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "grade"
},
{
"operator": "<=",
"value": 4,
"unit": "grade"
}
]
}
}
]
},
{
"exact_snippets": "LVEF<50%",
"criterion": "LVEF",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Hepatocellular abnormalities except if considered related to the BPDCN:",
"criterions": [
{
"exact_snippets": "Hepatocellular abnormalities",
"criterion": "hepatocellular abnormalities",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "1. ASAT (SGOT) and/or ALAT (SGPT) > 5 x ULN",
"criterions": [
{
"exact_snippets": "ASAT (SGOT) ... > 5 x ULN",
"criterion": "ASAT (SGOT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "ALAT (SGPT) > 5 x ULN",
"criterion": "ALAT (SGPT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 5,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "2. Total bilirubin ≥ 2.5 x ULN",
"criterions": [
{
"exact_snippets": "Total bilirubin ≥ 2.5 x ULN",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 2.5,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "* Creatinine level >1.5x ULN or creatinine clearance (MDRD)<50 mL/mn",
"criterions": [
{
"exact_snippets": "Creatinine level >1.5x ULN",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "creatinine clearance (MDRD)<50 mL/mn",
"criterion": "creatinine clearance (MDRD)",
"requirements": [
{
"requirement_type": "comparison",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "mL/mn"
}
}
]
}
]
},
{
"line": "* Prior thrombotic event",
"criterions": [
{
"exact_snippets": "Prior thrombotic event",
"criterion": "thrombotic event",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Active hepatitis B or C virus infection",
"criterions": [
{
"exact_snippets": "Active hepatitis B",
"criterion": "hepatitis B virus infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Active ... C virus infection",
"criterion": "hepatitis C virus infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* HIV positive",
"criterions": [
{
"exact_snippets": "HIV positive",
"criterion": "HIV status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
}
]
},
{
"line": "* Serious medical or psychiatric illness that could interfere with the completion of treatment",
"criterions": [
{
"exact_snippets": "Serious medical ... illness that could interfere with the completion of treatment",
"criterion": "serious medical illness",
"requirements": [
{
"requirement_type": "potential interference with treatment completion",
"expected_value": true
}
]
},
{
"exact_snippets": "Serious ... psychiatric illness that could interfere with the completion of treatment",
"criterion": "serious psychiatric illness",
"requirements": [
{
"requirement_type": "potential interference with treatment completion",
"expected_value": true
}
]
}
]
},
{
"line": "* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.",
"criterions": [
{
"exact_snippets": "Known allergy to any of the study medications",
"criterion": "allergy to study medications",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Known allergy to ... their analogues",
"criterion": "allergy to analogues of study medications",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Known allergy to ... excipients in the various formulations of any agent",
"criterion": "allergy to excipients in formulations",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Pregnant and lactating female patients",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactating female patients",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients diagnosed with or treated for another malignancy within 2 years before study enrollment or with residual disease (basal cell carcinoma or cervical carcinoma in situ patients may be enrolled if they have undergone complete resection)",
"criterions": [
{
"exact_snippets": "Patients diagnosed with or treated for another malignancy within 2 years before study enrollment",
"criterion": "another malignancy",
"requirements": [
{
"requirement_type": "diagnosis or treatment",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "residual disease",
"criterion": "residual disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "basal cell carcinoma or cervical carcinoma in situ patients may be enrolled if they have undergone complete resection",
"criterion": "basal cell carcinoma or cervical carcinoma in situ",
"requirements": [
{
"requirement_type": "resection",
"expected_value": "complete"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}